The paradox of 20q11.21 amplification in a subset of cases of myeloid malignancy with chromosome 20 deletion

Genes Chromosomes and Cancer

Volumn 49, Issue 11, 2010, Pages 998-1013

  MacKinnon, Ruth N ^a   Selan, Carly ^a   Wall, Meaghan ^a   Baker, Elizabeth ^b,c   Nandurkar, Harshal ^a,d   Campbell, Lynda J ^a,d  

^a ST VINCENT S HOSPITAL   (Australia)

^b KING EDWARD MEMORIAL HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHROMOSOME 20; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; COMPARATIVE GENOMIC HYBRIDIZATION; ERYTHROBLAST; ERYTHROID CELL; ERYTHROLEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE AMPLIFICATION; HUMAN; MYELODYSPLASTIC SYNDROME; ONCOGENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 20; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MYELODYSPLASTIC SYNDROMES; NUCLEIC ACID HYBRIDIZATION; POLYMERASE CHAIN REACTION;

EID: 77957555896     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20806     Document Type: Article

References (51)

1. Bench AJ, Nacheva EP, Hood TL, Holden JL, French L, Swanton S, Champion KM, Li J, Whittaker P, Stavrides G, Hunt AR, Huntly BJ, Campbell LJ, Bentley DR, Deloukas P, Green AR. 2000. Chromosome 20 deletions in myeloid malignancies: Reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene 19:3902-3913.
2. Bergeret E, Perrin J, Williams M, Grunwald D, Engel E, Thevenon D, Taillebourg E, Bruckert F, Cosson P, Fauvarque MO. 2008. TM9SF4 is required for Drosophila cellular immunity via cell adhesion and phagocytosis. J Cell Sci 121:3325-3334.
3. Bram S, Swolin B, Rodjer S, Stockelberg D, Ogard I, Back H. 2003. Is monosomy 5 an uncommon aberration? Fluorescence in situ hybridization reveals translocations and deletions in myelodysplastic syndromes or acute myelocytic leukemia. Cancer Genet Cytogenet 142:107-114.
4. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE, Jr. 1998. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 18:2553-2558.
5. Davis MP, Dewald GW, Pierre RV, Hoagland HC. 1984. Hematologic manifestations associated with deletions of the long arm of chromosome 20. Cancer Genet Cytogenet 12:63-71.
6. Dos Santos C, Demur C, Bardet V, Prade-Houdellier N, Payrastre B, Recher C. 2008. A critical role for Lyn in acute myeloid leukemia. Blood 111:2269-2279.
7. Douet-Guilbert N, Basinko A, Morel F, Le Bris MJ, Ugo V, Morice P, Berthou C, De Braekeleer M. 2008a. Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: Characterization by molecular cytogenetics of commonly deleted and retained regions. Ann Hematol 87:537-544.
8. Douet-Guilbert N, Lai JL, Basinko A, Gueganic N, Andrieux J, Pollet B, Plantier I, Delattre C, Crepin O, Corm S, Le Bris MJ, Morel F, De Braekeleer M. 2008b. Fluorescence in situ hybridization characterization of ider(20q) in myelodysplastic syndrome. Br J Haematol 143:716-720.
9. Falzetti D, Vermeesch JR, Hood TL, Nacheva EP, Matteucci C, Martelli MF, Van den Berghe H, Marynen P, Mecucci C. 1999. Identification of multiple copies of a 20q-chromosome in a case of myelodysplastic syndrome: A FISH study. Leuk Res 23:407-413.
10. Fenaux P, Morel P, Lai JL. 1996. Cytogenetics of myelodysplastic syndromes. Semin Hematol 33:127-138.
11. Fu L, Nara N, Tohda S. 2007. Involvement of Notch signaling in myelodysplastic syndrome. Leuk Res 31:1160-1161.
12. Ghoshal Gupta S, Baumann H, Wetzler M. 2008. Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia. Leuk Res 32:1005-1014.
13. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. 1997. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088.
14. Halupa A, Bailey ML, Huang K, Iscove NN, Levy DE, Barber DL. 2005. A novel role for STAT1 in regulating murine erythropoiesis: Deletion of STAT1 results in overall reduction of erythroid progenitors and alters their distribution. Blood 105: 552-561.
15. Heim S, Mitelman F. 1992. Cytogenetic analysis in the diagnosis of acute leukemia. Cancer 70:1701-1709.
16. Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, Makishima H, Jankowska AM, Jiang, Y, Verma A, Theil KS, McDevitt MA, Maciejewski JP. 2010. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis. Genes Chromosomes Cancer 49:390-399.
17. ISCN. 2009. An International System for Human Cytogenetic Nomenclature. LG Shaffer, ML Slovak, LJ Campbell, editors. Basel: S. Karger.
18. Kirito K, Uchida M, Takatoku M, Nakajima K, Hirano T, Miura Y, Komatsu N. 1998. A novel function of Stat1 and Stat3 proteins in erythropoietin-induced erythroid differentiation of a human leukemia cell line. Blood 92:462-471.
19. Kirito K, Nakajima K, Watanabe T, Uchida M, Tanaka M, Ozawa K, Komatsu N. 2002. Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation. Blood 99:102-110.
20. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE, Skorski T. 2002. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 21:5766-5774.
21. Kubonishi I, Muneishi H, Hashimoto E, Hatakeyama N, Kuzume T, Miyoshi I. 1996. Duplication of del(20)(q11) in a case of MDS. Cancer Genet Cytogenet 86:185-186.
22. Kurtin PJ, Dewald GW, Shields DJ, Hanson CA. 1996. Hematologic disorders associated with deletions of chromosome 20q: A clinicopathologic study of 107 patients. Am J Clin Pathol 106:680-688.
23. Landrette SF, Kuo YH, Hensen K, Barjesteh van Waalwijk van Doorn-Khosrovani S, Perrat, PN, Van de Ven WJ, Delwel R, Castilla LH. 2005. Plag1 and Plagl2 are oncogenes that induce acute myeloid leukemia in cooperation with Cbfb-MYH11. Blood 105:2900-2907.
24. Lee EJ, Schiffer CA, Misawa S, Testa JR. 1987. Clinical and cytogenetic features of familial erythroleukaemia. Br J Haematol 65:313-320.
25. Li J, Bench AJ, Vassiliou GS, Fourouclas N, Ferguson-Smith AC, Green AR. 2004a. Imprinting of the human L3MBTL gene: A polycomb family member located in a region of chromosome 20 deleted in human myeloid malignancies. Proc Natl Acad Sci USA 101:7341-7346.
26. Li T, Xue Y, Wu Y, Pan J. 2004b. Clinical and molecular cytogenetic studies in seven patients with myeloid diseases characterized by i(20q-). Br J Haematol 125:337-342.
27. Lionberger JM, Wilson MB, Smithgall TE. 2000. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem 275:18581-18585.
28. Lu L, Stanley P. 2006. Roles of O-fucose glycans in notch signaling revealed by mutant mice. Methods Enzymol 417:127-136.
29. MacGrogan D, Alvarez S, DeBlasio T, Jhanwar SC, Nimer SD. 2001. Identification of candidate genes on chromosome band 20q12 by physical mapping of translocation breakpoints found in myeloid leukemia cell lines. Oncogene 20:4150-4160.
30. MacGrogan D, Kalakonda N, Alvarez S, Scandura JM, Boccuni P, Johansson B, Nimer SD. 2004. Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells. Genes Chromosomes Cancer 41:203-213.
31. MacKinnon RN, Campbell LJ. 2005. A comparison of two contrasting recurrent isochromosomes 20 found in myelodysplastic syndromes suggests that retention of proximal 20q is a significant factor in myeloid malignancies. Cancer Genet Cytogenet 163:176-179.
32. MacKinnon RN, Campbell LJ. 2007. Dicentric chromosomes and 20q11.2 amplification in MDS/AML with apparent monosomy 20. Cytogenet Genome Res 119:211-220.
33. MacKinnon RN, Campbell LJ. Monosomy 20 in the karyotypes of myeloid malignancies is usually the result of misclassification of unbalanced chromosome 20 abnormalities., In: Urbano KV, editor. Advances in Genetic Research. Nova Science Publishers, (in press).
34. MacKinnon RN, Patsouris C, Chudoba I, Campbell LJ. 2007. A FISH comparison of variant derivatives of the recurrent dic(17;20) of myelodysplastic syndromes and acute myeloid leukemia: Obligatory retention of genes on 17p and 20q may explain the formation of dicentric chromosomes. Genes Chromosomes Cancer 46:27-36.
35. Mitelman F, Johansson B, Mertens FE. 2010. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. Available at: http://cgap.nci.nih.gov/Chromosomes/Mitelman.
36. Moore MA. 2005. Converging pathways in leukemogenesis and stem cell self-renewal. Exp Hematol 33:719-737.
37. Nacheva E, Holloway T, Carter N, Grace C, White N, Green AR. 1995. Characterization of 20q deletions in patients with myelo-proliferative disorders or myelodysplastic syndromes. Cancer Genet Cytogenet 80:87-94.
38. Ohyashiki K, Murakami T, Ohyashiki JH, Kodama A, Sakai N, Ito H, Toyama K. 1992. Double 20q- anomaly in myelodysplastic syndrome. Cancer Genet Cytogenet 58:174-176.
39. Pene-Dumitrescu T, Peterson LF, Donato NJ, Smithgall TE. 2008. An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. Oncogene 27:7055-7069.
40. Quintrell N, Lebo R, Varmus H, Bishop JM, Pettenati MJ, Le Beau MM, Diaz MO, Rowley JD. 1987. Identification of a human gene (HCK) that encodes a protein-tyrosine kinase and is expressed in hemopoietic cells. Mol Cell Biol 7:2267- 2275.
41. Rucker FG, Bullinger L, Schwaenen C, Lipka DB, Wessendorf S, Frohling S, Bentz M, Miller S, Scholl C, Schlenk RF, Radlwimmer B, Kestler HA, Pollack JR, Lichter P, Dohner K, Dohner H. 2006. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 24:3887-3894.
42. Schreiner SJ, Schiavone AP, Smithgall TE. 2002. Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J Biol Chem 277:45680-45687.
43. Shannon KM, Le Beau MM. 2008. Cancer: Hay in a haystack. Nature 451:252-253.
44. Silva CM. 2004. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 23: 8017-8023.
45. Smoley SA, Fink SR, Paternoster SF, Stockero KJ, Nguyen LP, Nguyen PL, Hanson CA, Dewald GW. 2007. Frequency, hematopathology, and detection of a new isodicentric variant of deletion 20q. Cancer Genet Cytogenet 173:144-149.
46. Spiekermann K, Biethahn S, Wilde S, Hiddemann W, Alves F. 2001. Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol 67:63-71.
47. Stahl M, Uemura K, Ge C, Shi S, Tashima Y, Stanley P. 2008. Roles of Pofut1 and O-fucose in mammalian Notch signaling. J Biol Chem 283:13638-13651.
48. Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL, DeWald GW, Kaufmann SH. 2006. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 20:971-978.
49. Vardiman JW, Harris NL, Brunning RD. 2002. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302.
50. Ziegler SF, Marth JD, Lewis DB, Perlmutter RM. 1987. Novel proteintyrosine kinase gene (hck) preferentially expressed in cells of hematopoietic origin. Mol Cell Biol 7:2276-2285.
51. hck. Mol Cell Biol 9:2724-2727.